Radiotherapy | Nano Publications

2019 – ESMO – NBTXR3 activated by SBRT in liver cancers

Abstracts, Donnée clinique de NBTXR3, Foie

Treatment of hepatocellular carcinoma (HCC) and liver metastasis (mets) is challenging due to presence of underlying disease, e.g. cirrhosis. Stereotactic body radiation therapy (SBRT) is a well-tolerated alternative for inoperable patients (pts), yet maximal dose to the tumor is limited by potential toxicity to surrounding healthy tissues. Otherwise inert, NBTXR3 (hafnium oxide nanoparticles) when acti- vated by ionizing radiation (RT) augments dose deposit within tumor cells, increasing tumor cell death compared to RT alone. […]

Continuer la lecture…

2019 – ASTRO – NBTXR3 for the treatment liver cancers

Abstracts, Donnée clinique de NBTXR3, Foie

The medical community faces important challenges to treat liver cancer because of underlying disease. Reduction of healthy tissue irradiation while at the same time increasing energy dose deposit within tumor cells still constitutes a challenge in radiation oncology. NBTXR3, hafnium oxide nanoparticles, increase energy deposit inside tumor cells only when activated by ionizing radiation such as stereotactic body radiotherapy (SBRT) and thus increase tumor cell death compared to radiation alone. […]

Continuer la lecture…

2019 – ASTRO – NBTXR3 generates an anti tumor immune response

Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy (RT) increase radiation dose deposit within cancer cells compared to RT alone. Currently 7 clinical trials are underway to evaluate NBTXR3+RT. To date, no dose limiting toxicities (DLTs) have been observed. Given that RT can prime an anti-tumor immune response we hypothesized that this response could be enhanced by NBTXR3+RT in both animals and humans. […]

Continuer la lecture…

2019 – ESMO WGI – NBTXR3 in unresectable liver cancers

Abstracts, Donnée clinique de NBTXR3, Foie

The treatment of liver cancers is challenging in part due to the presence of underlying liver diseases. In patients unsuitable for surgery, interventional radiation oncology approaches, i.e. minimally invasive image guided therapeutic procedures, offer new treatment opportunities and can achieve good local control. NBTXR3, hafnium oxide nanoparticles, administered via intratumoral injection, increases energy deposit inside tumor cells only when activated by ionizing radiation such as stereotactic body radiotherapy (SBRT) and thus increase tumor cell death compared to radiation alone. […]

Continuer la lecture…

2019 – ASCO – NBTXR3 in Liver Cancers

Abstracts, Donnée clinique de NBTXR3, Foie

Hafnium oxide nanoparticles, NBTXR3, increase the effect of radiotherapy (RT) by enhancing local energy dose deposit within tumor cells, resulting in increased cell death compared to the same dose of RT alone. NBTXR3 efficacy was demonstrated in a phase II/III study in soft tissue sarcoma (NCT02379845) and is currently evaluated in other solid tumors including liver cancers. The use of this radio enhancer is particularly relevant in liver cancer management, a difficult to treat heterogenous population, due to the presence of underlying liver dysfunction. […]

Continuer la lecture…

2019 – ASCO – NBTXR3 induces antitumor immune response

Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Radiotherapy (RT) can prime an anti-tumor immune response. Unfortunately, this response rarely generates total tumor destruction and abscopal effect. When activated by RT, intratumorally (IT) administered hafnium oxide nanoparticles (NBTXR3) locally increase radiation dose deposit and tumor cell death compared to RT alone. We hypothesized that NBTXR3 + RT could enhance the anti-tumor immune response, both in mice and humans. […]

Continuer la lecture…

2019 – ASCO – Phase I NBTXR3 in elderly/frail HNSCC patients

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

New therapeutic approaches are needed for elderly or frail head and neck squamous cell carcinoma (HNSCC) patients (pts) ineligible for standard of care treatment. NBTXR3, a crystalline solution of hafnium oxide nanoparticles may represent such an option. Injected intratumorally, NBTXR3 enters tumor cells and yields an increased cell-localized energy deposit upon exposure to radiotherapy (RT), leading to increased tumor cell death compared to the same dose of RT alone. […]

Continuer la lecture…

2019 – AHNS – Phase I/II NBTXR3 in combination with anti-PD-1

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Preoperative radiotherapy (RT) is an option for a subset of patients with locally advanced primary or relapsed tumors. Yet, its impact on efficacy in terms of pathological response is limited, highlighting the need for novel multimodal therapies aimed at local control with low toxicity. NBTXR3 is made of hafnium oxide nanoparticles which, injected intratumorally (IT) and activated by ionizing radiation, yield a tumor-localized high energy deposit and increase cell death compared to the same dose of RT alone. […]

Continuer la lecture…

2019 – ESTRO – Randomized NBTXR3 trial in STS

Abstracts, Donnée clinique de NBTXR3, STM

Continuer la lecture…

2019 – ASCO-SITC – NBTXR3 with anti-PD-1 in advanced HNSCC or NSCLC

Abstracts, Donnée clinique de NBTXR3, Poumon, Tête & Cou

Despite proven efficacy, a limited number of patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or metastatic non-small cell lung cancer (NSCLC) benefit from anti-PD-1 treatment. Indeed, most pts do not respond to initial therapy due to intrinsic re-sistance to checkpoint inhibition. There is thus an important unmet medical need for a curative treatment in these pts and converting the local immune microenvironment to a “hot” phenotype may help to overcome therapeutic resistance. […]

Continuer la lecture…